DEA Judge Orders New Replies as Marijuana Rescheduling Stays Stalled

What the judge ordered, and what isn't yet public

A DEA administrative law judge has ordered a new round of replies, and the rescheduling process remains sidelined, according to Cannabis Business Times. That headline is the only published detail CannIntel could verify.

We hadn't reviewed the order itself, the docket entry or any filing deadlines as of publication. The judge's name, the parties told to respond and the due dates are therefore not reported here. Nothing in the headline points to a hearing date.

Those details will matter more than the framing. A procedural order tells you who is still in the room and what the judge thinks must be settled first.

How the proceeding got here

The process traces to a proposal to move marijuana from Schedule I to Schedule III, published by the Department of Justice on May 21, 2024. The NPRM followed an August 2023 recommendation from HHS to reclassify the plant.

A formal hearing before a DEA administrative law judge was set to begin in January 2025. It was stayed that month while an interlocutory appeal was pending. Since then, the proceeding has been defined less by what it decided than by what it hasn't.

Not a good record for a rule once billed as imminent.

Why a replies order isn't a ruling

An order for new replies is a procedural step and doesn't amount to a decision on whether marijuana belongs in Schedule III. Nothing is decided. No final rule exists, and marijuana remains a Schedule I controlled substance under federal law today.

Every round of briefing adds time, and time is the scarcest asset for operators who have been waiting on this since the HHS recommendation. Readers should resist treating any judicial activity as movement toward a finish line. Activity and progress are different things.

The operator lens: 280E doesn't go away on a headline

Section 280E of the Internal Revenue Code denies ordinary business deductions to businesses trafficking in Schedule I and II substances. Moving marijuana to Schedule III is the mechanism most operators expect to end that burden.

Until a final rule is published and effective, that relief is theoretical. Multi-state operators that built tax reserves, covenant assumptions or capital plans around a 2026 reclassification should be stress-testing the opposite case. A stalled proceeding means the 280E bill keeps arriving.

Treating rescheduling as a balance-sheet event before it's a legal one is the kind of optimism this record doesn't support.

What Schedule III wouldn't change

Schedule III reclassification wouldn't by itself legalize adult-use sales or override state licensing regimes in California, Ohio or anywhere else. State-licensed markets would continue to operate under state law, and the federal-state conflict over interstate commerce would persist.

Patients and investors should keep that boundary in view. Rescheduling is a tax and research story first. It isn't a federal legalization story, and a delay in the DEA process doesn't alter what state programs can do today, although it prolongs the uncertainty hanging over them.

What the record needs to show

The documents that will settle this are the ALJ's order, the docket and the Federal Register, not trade-press summaries. Each should be pulled directly and read against the others before anyone declares a new phase of the process.

The timeline we can support is short: an NPRM in May 2024, a hearing stayed in January 2025 and a new replies order reported on October 14, 2026. Gaps between those dates are where reporting is still owed. For full background on the sequence, see the CannIntel topic hub on DEA cannabis rescheduling.

We'll update this report when the order text is available and the deadlines can be confirmed against the docket.

What to watch next

The next signals are the response deadlines in the judge's order and whether any hearing date follows. A posted schedule would be the first real evidence that the proceeding is moving again.

Absent one, the working assumption for operators, lenders and investors should be that Schedule I treatment and 280E exposure continue, with the DEA docket and the Federal Register as the only sources worth trusting.